Spain's WerfenLife acquires US-based Accriva Diagnostics for $380M to strengthen its In Vitro Diagnostics division.

10/02/2017
Diego Gutiérrez
Spain's WerfenLife acquires US-based Accriva Diagnostics for $380M to strengthen its In Vitro Diagnostics division.
WerfenLife, the Catalan medical giant with an annual turnover of €1.175 million, wants to boost its in vitro diagnostics division and has bought Accriva Diagnostics and Germany's Tem. On the other hand, it wants to reduce the weight of its medical devices division and intends to sell Bolton Medical.
Werfenlife Corporate finance analysis

WerfenLife, es un gigante médico que factura €1.175M anuales y que no ha para de crecer. La empresa tiene tres divisiones: in vitro diagnostics and medical material distribution and medical devices. Although all three divisions are growing year on year, the medical devices division has the smallest share of sales and WerfenLife has decided to specialise its group in the larger, more scalable and profitable divisions: in vitro diagnostics and medical material distribution. That is why it is divesting its devices division and raising resources for its diagnostics division.

Last year they were planning to go public, but in the end they did not go public because the company was profitable. As long as WerfenLife has this capacity to generate funds, the Rubiralta brothers do not plan to go to the stock market.

Acquisition of Accriva Diagnostics for €358M

San Diego-based Accriva, which had a turnover of $94 million in 2016, develops, produces and distributes diagnostic tests for coagulation.

WerfenLife ha explicado que la cartera de productos de Accriva, que cuenta con 460 empleados, tiene un «alto encaje estratégico» en el negocio de Werfen, la división que aglutina el negocio de diagnóstico in vitro de WerfenLife.

This acquisition complements the acquisition of Germany's Tem, also in the in vitro diagnostics segment.

Purchase of Tem in 2016

In October 2016 Werfenlife bought Tem, for €125M.

Tem, which also operates in the US, specialises in the development, production and distribution of diagnostic tests that help to make better decisions about the need for blood transfusion and the use of blood products. The company has a turnover of around €30M.

Other posts that may interest you

If you are looking for investors, you want to buy and selling a companyplease contact us. Abra-Invest has a team of experts in each area at your disposal. Call +34 946424142 or fill in the contact form.

Lastest news

Webinar | Cómo maximizar el valor de tu empresa antes de vender

INFORMACIÓN IMPORTANTE: La inscripción y participación en los webinars es totalmente anónima para terceros Cómo maximizar el valor de tu empresa antes de vender Maximizar el valor de tu empresa antes de vender es, casi siempre, el trabajo más rentable que puede hacer...

The State of technology M&A in Spain | May 2026 Analysis

El M&A tecnológico en España registró en mayo de 2026 36 operaciones identificadas con un importe agregado conocido de aproximadamente 720,7 millones de euros. La cifra es una referencia mínima: 13 transacciones no hicieron público su importe. El mes combinó...

Notable technology M&A deals in Spain | Analysis: April 2026

The market for the sale and acquisition of technology companies in Spain once again saw particularly brisk activity in April 2026. The month saw significant deals in vertical software, cybersecurity, cloud computing, payments, artificial intelligence, telecommunications...

What does Constellation Software teach us about real value in tech M&A?

An analysis by Diego Gutiérrez Zarza, Partner at Baker Tilly Tech M&A For years, growth was enough to build value in a technology company. That is no longer the case. The market continues to pay a premium for good software companies, but it no longer rewards growth for its own sake...

Do you want to sell or buy a company?

We are experts in M&A transactions in the technology sector.

Subscribe to our newsletter

    On which topic would you like to receive information?

    Request for information

    If you want to buy or sell a company, or need more information about our services, do not hesitate to contact us through the form.

    Or if you prefer, call us at:

    +34 946 42 41 42